Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 04-Oct-24 5:29 PM View:  | Dube Michael P VP, Chief Accounting Officer | Intellia Therapeutics, Inc. (NTLA) | 02-Oct-24 | Sale | 2,012 | $19.01 | $38,248.10 | (4%) 49.02K to 47.01K | |
| 24-Jul-24 4:17 PM View: | Dulac Edward J III EVP, Chief Financial Officer | Intellia Therapeutics, Inc. (NTLA) | 22-Jul-24 | Grant | 66,324 | -- | -- | 100% 0 to 66.32K | |
| 03-Jul-24 1:15 PM View: | Dube Michael P VP, PAO and Interim PFO | Intellia Therapeutics, Inc. (NTLA) | 01-Jul-24 | Grant | 17,801 | -- | -- | 57% 31.22K to 49.02K | |
| 03-Jul-24 1:15 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Jul-24 | Sale | 405 | $22.93 | $9,286.65 | (< 1%) 71.88K to 71.47K | |
| 20-Jun-24 5:00 PM View: | Verwiel Frank Director | Intellia Therapeutics, Inc. (NTLA) | 17-Jun-24 | Sale (Planned) | 1,505 | $25.00 | $37,625.00 | (8%) 19.45K to 17.95K | |
| 17-Jun-24 5:14 PM View: | Goff Brian Director | Intellia Therapeutics, Inc. (NTLA) | 13-Jun-24 | Grant | 15,409 | -- | -- | 100% 0 to 15.41K | |
| 14-Jun-24 4:18 PM View: | Bhanji Muna Director | Intellia Therapeutics, Inc. (NTLA) | 12-Jun-24 | Grant | 7,737 | -- | -- | 64% 12.0K to 19.73K | |
| 14-Jun-24 4:22 PM View: | Verwiel Frank Director | Intellia Therapeutics, Inc. (NTLA) | 12-Jun-24 | Grant | 7,737 | -- | -- | 66% 11.72K to 19.45K | |
| 14-Jun-24 4:19 PM View: | Cohen Fred E Director | Intellia Therapeutics, Inc. (NTLA) | 12-Jun-24 | Grant | 7,737 | -- | -- | 19% 41.72K to 49.45K | |
| 14-Jun-24 4:20 PM View: | Goodman Jesse Director | Intellia Therapeutics, Inc. (NTLA) | 12-Jun-24 | Grant | 7,737 | -- | -- | 66% 11.72K to 19.45K | |
| 14-Jun-24 4:21 PM View: | Keresty Georgia Director | Intellia Therapeutics, Inc. (NTLA) | 12-Jun-24 | Grant | 7,737 | -- | -- | 48% 16.15K to 23.88K | |
| 14-Jun-24 4:16 PM View: | Chase William J Director | Intellia Therapeutics, Inc. (NTLA) | 12-Jun-24 | Grant | 7,737 | -- | -- | 41% 18.96K to 26.69K | |
| 05-Mar-24 4:10 PM View: | Basta James EVP, General Counsel | Intellia Therapeutics, Inc. (NTLA) | 04-Mar-24 | Sale | 2,297 | $32.99 | $75,778.00 | (3%) 83.87K to 81.57K | |
| 05-Mar-24 4:10 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 04-Mar-24 | Sale | 605 | $32.99 | $19,959.00 | (< 1%) 72.08K to 71.47K | |
| 05-Mar-24 4:10 PM View: | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 37,966 | -- | -- | 86% 43.93K to 81.89K | |
| 05-Mar-24 4:10 PM View: | Basta James EVP, General Counsel | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 32,394 | -- | -- | 63% 51.47K to 83.87K | |
| 05-Mar-24 4:10 PM View: | Goddard Glenn EVP, Chief Financial Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 28,628 | -- | -- | 71% 40.59K to 69.21K | |
| 05-Mar-24 4:10 PM View: | Hicks Derek EVP, Chief Business Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 29,393 | -- | -- | 79% 36.99K to 66.38K | |
| 05-Mar-24 4:10 PM View: | Leonard John M. President and CEO Director | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 113,586 | -- | -- | 13% 904.9K to 1.02M | |
| 05-Mar-24 4:10 PM View: | Lebwohl David EVP, Chief Medical Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 38,701 | -- | -- | 71% 54.37K to 93.07K | |
| 05-Mar-24 4:10 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-24 | Grant | 31,230 | -- | -- | 76% 40.84K to 72.08K | |
| 10-Jan-24 4:15 PM View: | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Intellia Therapeutics, Inc. (NTLA) | 08-Jan-24 | Sale (Planned) | 2,275 | $28.87 | $65,681.70 | (5%) 46.2K to 43.93K | |
| 05-Jan-24 4:50 PM View: | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 5,532 | $29.46 | $162,973.00 | (11%) 51.73K to 46.2K | |
| 05-Jan-24 4:49 PM View: | Goddard Glenn EVP, Chief Financial Officer | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 5,365 | $29.46 | $158,053.00 | (12%) 45.95K to 40.59K | |
| 05-Jan-24 4:50 PM View: | Lebwohl David EVP, Chief Medical Officer | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 5,843 | $29.46 | $172,135.00 | (10%) 60.22K to 54.37K | |
| 05-Jan-24 4:44 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 4,608 | $29.50 | $135,954.00 | (10%) 45.45K to 40.84K | |
| 05-Jan-24 4:51 PM View: | Leonard John M. President and CEO Director | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 19,223 | $29.46 | $566,310.00 | (2%) 924.12K to 904.9K | |
| 05-Jan-24 4:45 PM View: | Basta James EVP, General Counsel | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 3,805 | $29.46 | $112,095.00 | (7%) 55.28K to 51.47K | |
| 05-Jan-24 4:46 PM View: | Hicks Derek EVP, Chief Business Officer | Intellia Therapeutics, Inc. (NTLA) | 03-Jan-24 | Sale | 3,877 | $29.46 | $114,216.00 | (9%) 40.86K to 36.99K | |
| 03-Jan-24 5:35 PM View: | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Jan-24 | Option Exercise | 3,500 | -- | -- | 7% 48.23K to 51.73K | |
| 03-Jan-24 5:28 PM View: | Goddard Glenn EVP, Chief Financial Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Jan-24 | Option Exercise | 3,062 | -- | -- | 7% 42.89K to 45.95K | |
| 03-Jan-24 5:30 PM View: | Leonard John M. President and CEO Director | Intellia Therapeutics, Inc. (NTLA) | 01-Jan-24 | Option Exercise | 7,848 | -- | -- | < 1% 916.28K to 924.12K | |
| 03-Jan-24 5:34 PM View: | Lebwohl David EVP, Chief Medical Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Jan-24 | Option Exercise | 3,187 | -- | -- | 6% 57.03K to 60.22K | |
| 02-Nov-23 4:42 PM View: | Bhanji Muna Director | Intellia Therapeutics, Inc. (NTLA) | 31-Oct-23 | Sale (Planned) | 265 | $23.90 | $6,333.50 | (2%) 12.26K to 12.0K | |
| 02-Aug-23 5:19 PM View: | Bhanji Muna Director | Intellia Therapeutics, Inc. (NTLA) | 31-Jul-23 | Sale (Planned) | 265 | $42.33 | $11,217.50 | (2%) 12.53K to 12.26K | |
| 10-Jul-23 5:21 PM View: | Bhanji Muna Director | Intellia Therapeutics, Inc. (NTLA) | 06-Jul-23 | Sale (Planned) | 1,867 | $39.30 | $73,373.10 | (13%) 14.39K to 12.53K | |
| 06-Jul-23 3:34 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 03-Jul-23 | Sale | 360 | $40.51 | $14,583.60 | (< 1%) 45.51K to 45.15K | |
| 22-Jun-23 5:52 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 20-Jun-23 | Planned Option Sale | 5,000 | $45.00 | $225,000.00 | (10%) 50.15K to 45.15K | |
| 22-Jun-23 5:52 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 20-Jun-23 | Option Exercise | 5,000 | $12.27 | $61,350.00 | 11% 45.15K to 50.15K | |
| 18-Apr-23 5:04 PM View: | Chase William J Director | Intellia Therapeutics, Inc. (NTLA) | 14-Apr-23 | Grant | 10,483 | -- | -- | 154% 6.8K to 17.28K | |
| 03-Mar-23 5:10 PM View: | Basta James EVP, General Counsel | Intellia Therapeutics, Inc. (NTLA) | 02-Mar-23 | Sale | 1,088 | $43.88 | $47,741.40 | (2%) 56.37K to 55.28K | |
| 03-Mar-23 5:10 PM View: | Basta James EVP, General Counsel | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 36,808 | -- | -- | 188% 19.56K to 56.37K | |
| 03-Mar-23 5:20 PM View: | Goddard Glenn EVP, Chief Financial Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 27,484 | -- | -- | 178% 15.4K to 42.89K | |
| 03-Mar-23 5:12 PM View: | Clark Eliana EVP, Chief Technical Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 30,673 | -- | -- | 212% 14.47K to 45.15K | |
| 03-Mar-23 5:18 PM View: | Leonard John M. President and CEO Director | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 91,036 | -- | -- | 11% 825.24K to 916.28K | |
| 03-Mar-23 5:15 PM View: | Lebwohl David EVP, Chief Medical Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 30,674 | -- | -- | 119% 25.69K to 56.36K | |
| 03-Mar-23 5:31 PM View: | Hicks Derek EVP, Chief Business Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 23,558 | -- | -- | 136% 17.31K to 40.86K | |
| 03-Mar-23 5:14 PM View: | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Intellia Therapeutics, Inc. (NTLA) | 01-Mar-23 | Grant | 29,938 | -- | -- | 170% 17.63K to 47.57K | |
| 06-Jan-23 5:39 PM View: | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Intellia Therapeutics, Inc. (NTLA) | 05-Jan-23 | Sale (Planned) | 2,330 | $38.48 | $89,658.90 | (12%) 19.96K to 17.63K | |
| 06-Jan-23 5:23 PM View: | Goddard Glenn EVP, Chief Financial Officer | Intellia Therapeutics, Inc. (NTLA) | 04-Jan-23 | Sale | 2,427 | $37.21 | $90,308.70 | (14%) 17.83K to 15.4K |
